While bone tissues have regenerative capabilities that enable self-repair of fractures, in extreme cases complete critical defect healing will not occur. Such bone defects in the craniofacial complex are often a result of birth defects, trauma or cancer surgery. Unfortunately, the long- term results of craniomaxillofacial reconstructions are very poor due to the overwhelming tissue fibrosis and scarring that occurs following surgery. This inflammatory-foreign body response to the grafted biomaterial remains one of the great challenges in treating these patients. To address this, our multi-institutional investigative team has sustained a long-term collaboration that produced several advances in this field including extraordinary success in treating several patients with facture non-unions non-surgically with recombinant parathyroid hormone (rPTH, teriparatide). To elucidate the mechanisms responsible for these rPTH effects on bone healing, and translate it to a Musculoskeletal Tissue Engineering (MTE) solution for critical bone defects, we published several preclinical discoveries. The most relevant to this renewal application are: 1) angiopoietins (Ang) 1 & Ang-2, which regulate large vessel vasculogenesis, are reciprocally regulated by rPTH therapy to inhibit large blood vessels proximal to the allograft; and 2) rPTH also inhibits the accumulation of pro-fibrotic mast cells adjacent to the large vessels. Based on this we hypothesize that rPTH therapy facilitates critical defect healing by: 1) its well-known anabolic effects on osteoblasts (Col1(2.3)+) to increase bone healing beyond the limits of a critical defect, 2) osteoblast-induced small vessel angiogenesis at the healing front, and 3) inhibitory effects on large vessel vasculogenesis, mast cell accumulation and fibrosis. Technologically, we: 1) developed a chronic cranial defect window chamber model for in vivo multiphoton laser scanning microscopy (MPLSM); 2) established a clinically relevant model of critical defect healing in the minipig mandible: 3) developed custom 3D-printed bone scaffolds to replace massive allografts; and 4) developed autologous osteogenic-iPS cells (iMSC) with enhanced bone forming properties and reduced transformation potential. Here we propose to use these innovative technologies to: 1) test our hypotheses on the nature of critical defects in craniofacial bones, 2) formally elucidate the mechanism by which rPTH therapy inhibits inflammation and fibrosis to allow for critical craniomaxillofacial bone defect healing, and 3) provide a translational MTE solution for this challenging clinical problem in a large animal model. Given the high clinical relevance of these proofs of concept, the potential impact of success could be huge for this significant problem.
Although approximately 100,000 bone grafts are performed each year to regenerated bone lost due to trauma or disease that are craniomaxillofacial in nature, the long-term results of these reconstructions are poor due to the overwhelming tissue fibrosis and scarring that occurs following surgery. This inflammatory, foreign body response to the grafted biomaterial remains one of the great challenges in treating patients with birth defects, traumatic injuries or cancers in the head and mouth. Recently, we have observed remarkable effects of the osteoporosis drug teriparatide (recombinant parathyroid hormone, PTH) in treating patients with fracture non-unions and animal models of bone grafting, in which the drug appears to resolve the fibrotic tissue and prevent the foreign body reaction. Here we propose to formally demonstrate that rPTH has these effects and could be used as an adjuvant therapy during craniomaxillofacial reconstructive surgery.
|Schwarz, Edward M (2017) Confirmation of Sexual Dimorphisms in Metal Hypersensitivity and Joint Pain Following Total Joint Arthroplasty: Commentary on an article by Marco S. Caicedo, PhD, et al.: ""Females with Unexplained Joint Pain Following Total Joint Arthroplasty Exhibit a H J Bone Joint Surg Am 99:e41|
|Cohn Yakubovich, Doron; Sheyn, Dmitriy; Bez, Maxim et al. (2017) Systemic administration of mesenchymal stem cells combined with parathyroid hormone therapy synergistically regenerates multiple rib fractures. Stem Cell Res Ther 8:51|
|Zhang, Longze; Wang, Tao; Chang, Martin et al. (2017) Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model. J Bone Miner Res 32:1870-1883|
|Wang, Tao; Zhang, Xinping; Bikle, Daniel D (2017) Osteogenic Differentiation of Periosteal Cells During Fracture Healing. J Cell Physiol 232:913-921|
|Zhang, Longze; Chang, Martin; Beck, Christopher A et al. (2016) Analysis of new bone, cartilage, and fibrosis tissue in healing murine allografts using whole slide imaging and a new automated histomorphometric algorithm. Bone Res 4:15037|
|Antebi, Ben; Zhang, Longze; Sheyn, Dmitriy et al. (2016) Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts. Bioengineering (Basel) 3:|
|Sheyn, Dmitriy; Shapiro, Galina; Tawackoli, Wafa et al. (2016) PTH Induces Systemically Administered Mesenchymal Stem Cells to Migrate to and Regenerate Spine Injuries. Mol Ther 24:318-330|
|Cohn Yakubovich, Doron; Tawackoli, Wafa; Sheyn, Dmitriy et al. (2015) Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts. J Vis Exp :e53459|
|Dhillon, Robinder S; Zhang, Longze; Schwarz, Edward M et al. (2014) The murine femoral bone graft model and a semiautomated histomorphometric analysis tool. Methods Mol Biol 1130:45-59|
|Nishitani, Kohei; Schwarz, Edward M (2014) Regenerative medicine: Cartilage transplants hold promise for challenging bone defects. Nat Rev Rheumatol 10:129-30|
Showing the most recent 10 out of 34 publications